Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
A study published in the February 15 issue of Clinical Infectious Diseases suggests that convalescent plasma may reduce the death rate in patients severely ill with this type of influenza.
Nanosphere, a leader in the development and commercialization of advanced molecular diagnostics systems, announced today FDA 510(k) clearance for the Verigene Respiratory Virus Plus Nucleic Acid Test on the Verigene System.
BioCryst Pharmaceuticals, Inc. today announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program.
How Swine Flu Overturned the Understanding of Pandemic Outbreaks. As H1N1 'Swine Flu' returns to the national headlines a new research paper reveals the key lessons about the origins of the 2009 pandemic. The paper, published today in BioEssays, reveals how the pandemic challenges the traditional understanding of 'antigenic shift', given that the virus emerged from an existing influenza subtype.
As we enter peak flu season, flu activity is steadily increasing in the United States, with eight states now reporting widespread outbreaks of influenza cases according to the most recent Centers for Disease Control and Prevention (CDC) report.
The antibodies produced by individuals who fought off H1N1 (swine flu) infection last year may bring researchers one step closer to their quest to develop a "universal" flu vaccine, U.S. researchers said Monday, HealthDay News/Bloomberg Businessweek reports.
OraSure Technologies, announced today the impending launch of the OraSure QuickFlu Rapid Flu A+B Test, a U.S. Food and Drug and Administration approved in vitro rapid qualitative test for the detection of influenza type A and type B, including H1N1 viral infections.
The search for a universal flu vaccine has received a boost from a surprising source: the 2009 H1N1 pandemic flu strain.
Only one week into the new year swine flu has already claimed several lives. Healthmap.org believes that swine flu has resulted in hospitalization and even death not only in the UK, but also in other parts of Europe and America. Reports indicate that the virus is even more virulent than last year.
While most blood tests require shipping a vial of blood to a laboratory for analysis and waiting several days for the results, a new device invented by a team of engineers and students at the University of Rhode Island uses just a pinprick of blood in a portable device that provides results in less than 30 minutes.
With rise of incidence of flu this winter emergency stocks of the vaccine are being released. A review is to be carried out into whether vaccines should be purchased centrally next year in order to avoid shortages. At present the GPs can procure the jabs directly from manufacturers according to their estimates of patient requirement.
For those infected with the 2009 pandemic influenza A (H1N1) virus, extreme obesity was a powerful risk factor for death, according to an analysis of a public health surveillance database. In a study to be published in the February 1, 2011, issue of Clinical Infectious Diseases, researchers associated extreme obesity with a nearly three-fold increased odds of death from 2009 H1N1 influenza. Half of Californians greater than 20 years of age hospitalized with 2009 H1N1 were obese.
As the UK and a number of European countries are now experiencing epidemics of influenza, including A(H1N1) which was the 2009 pandemic virus, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) warns that the consequences of non-vaccination could emerge as a new flu emergency and are calling for greater efforts to encourage vaccination, not only for at risk groups but also health care workers.
Parents of kids returning to school in the UK after Christmas holidays have been warned of a surge in flu cases. Professor John Oxford, a leading virologist at St Bartholomew’s and the Royal London Hospital explained that children returning to school in the past prompted a rise in the number of flu cases. “You tend to get a surge,” the professor said. “I would anticipate a surge, but how long that will last is difficult to say.” He added, “This virus is not going to go away next week. Even if it’s already peaked, it’s still going to be around for the next couple of weeks and it’s still worthwhile being vaccinated at this stage.”
A complimentary planning tool is now available to help the nation's nursing homes prepare for an influenza pandemic. The new resource is courtesy of the New Jersey Hospital Association, with grant funding from Hoffman-LaRoche.
The flu season continues to affect more people. Experts have warned the Britons are still at risk as the surge in flu cases has still not yet peaked. The cases would increase they warn, over the next two to four weeks. World Health Organization released figures that show the rate of influenza-like illnesses is still low across continental Europe but has risen dramatically in Britain since the flu season began in October.
SinoFresh® HealthCare, Inc., is pleased to announce that its marketing division has secured an agency marketing relationship with Green Valley Drug, the largest medical supplier in Southern Nevada with a significant pharmacy and medical customer base in the western U.S.
As number of cases of flu rise in the UK, Health Secretary Andrew Lansley is under pressure to strengthen the flu vaccination campaign. He reinstated a public health “Catch It, Bin It, Kill It” advertising campaign after he was warned by government advisers of the need to improve immunization rates which are at their lowest this winter for many years. It had been discontinued despite helping educate the public to adopt good hygiene habits during last year’s H1N1 swine flu epidemic at a cost of just £609,000. There were 12 more deaths in the last week from flu, bringing the total this winter to 39, the Health Protection Agency (HPA) said today. Thirty-six were killed by H1N1 swine flu, which is the most virulent of the two main flu strains currently circulating. The others died after contracting Influenza B, the other strain. All except one of the 39 were under 65 and four were under five.
CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.